ANO1 and cancer: High ANO1 expression also reprograms cholesterol metabolism by inhibiting LXR-mediated cholesterol efflux, leading to intracellular cholesterol accumulation, which enhances cancer cell survival, increases metastatic potential, and is linked to resistance to anti-PD-1 therapy (178, 199).